Back to Search
ROBERT BOK, MD, PHD
MD, PHD
Medical Oncology Physician
NPI: 1235312323Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
A51379(CA)
Research & Publications (20)
Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015.
PMID 18728723·Ther Clin Risk Manag·2008
8-other
In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate.
PMID 17659629·Magn Reson Med·2007
7-preclinical
Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model.
PMID 14663466·Prostate Cancer Prostatic Dis·2003
7-preclinical
Bloodborne biomolecular markers in prostate cancer development and progression.
PMID 12459730·Nat Rev Cancer·2002
6-review
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
PMID 11289126·Cancer Res·2001
8-other
Imaging considerations for in vivo 13C metabolic mapping using hyperpolarized 13C-pyruvate.
PMID 19319902·Magn Reson Med·2009
7-preclinical
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.
PMID 18922937·Cancer Res·2008
7-preclinical
Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studies.
PMID 18479878·Magn Reson Imaging·2008
7-preclinical
Current and potential applications of clinical 13C MR spectroscopy.
PMID 18322118·J Nucl Med·2008
6-review
Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience.
PMID 17969006·Magn Reson Med·2007
7-preclinical
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
PMID 16369983·Cancer·2006
3-trial
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
PMID 15289492·J Clin Oncol·2004
3-trial
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
PMID 15221993·Cancer·2004
3-trial
Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype.
PMID 14991759·J Cell Biochem·2004
6-review
Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.
PMID 12506177·J Clin Oncol·2003
3-trial
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
PMID 12131305·J Urol·2002
8-other
Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate.
PMID 11798065·Differentiation·2001
7-preclinical
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
PMID 11685733·Semin Oncol·2001
3-trial
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.
PMID 11054432·J Clin Oncol·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1700 4TH ST, SUITE 201, BYERS HALL, UCSF
SAN FRANCISCO, CA 94158 - Phone
- (415) 514-9716
Quick Facts
- NPI
- 1235312323
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile